RE:RE:RE:RE:RE:RE:RE:RE:Here is the link Great, so this back and forth is about interfering with you retirement plans?
I think you want a steady and predictable outcome here, but you are not going to get it. Maybe there is no deal?
This is a junior biotech and IF they land the great deals then this becomes a roller coaster of buying and selling and postulation about growth possibilities. If they land the kind of deal that PRC is laying out, then it will become a question of whether the market wants in big time now or over time. If you look at Sernova, they blew past $1 easy now well beyond post settling. It's about the tech at that point, nothing personal. My personal views are that the higher valuations are absolutely possible.. IF they deliver.
Any new base will be founded over the mid to longer run premised upon the accounting fundamentals with a revised market sentiment about the company's future prospects. This can change because it is a fact that an established relationship with a top 5 or top 10 non Chinese pharmaceutical (lets hope) will ultimately open the doors wide whether the current Ceo is in chair or not.